Neurizon locks in global trademark protection across key pharma markets

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions

China nod to first homegrown BNCT cancer drug for human trials

The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint

The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs